Literature DB >> 21965145

Copy number alterations in prostate tumors and disease aggressiveness.

Iona Cheng1, Albert M Levin, Yu Chuan Tai, Sarah Plummer, Gary K Chen, Christine Neslund-Dudas, Graham Casey, Benjamin A Rybicki, John S Witte.   

Abstract

Detecting genomic alterations that result in more aggressive prostate cancer may improve clinical treatment and our understanding of the biology underlying this common but complex disease. To this end, we undertook a genome-wide copy number alterations (CNAs) study of clinicopathological characteristics of 62 prostate tumors using the Illumina 1M single nucleotide polymorphism array. The highest overall frequencies of CNAs were on chromosomes 8q (gains), 8p (loss and copy-neutral), and 6q (copy-loss). Combined loss and copy-neutral events were associated with increasing disease grade (P = 0.03), stage (P = 0.01), and diagnostic prostate specific antigen (PSA) (P = 0.01). Further evaluation of CNAs using gene ontology identified pathways involved with disease aggressiveness. The "regulation of apoptosis" pathway was associated with stage of disease (P = 0.004), while the "reproductive cellular process" pathway was associated with diagnostic PSA (P = 0.00038). Specific genes within these pathways exhibited strong associations with clinical characteristics; for example, in the apoptosis pathway BNIP3L was associated with increasing prostate tumor stage (P = 0.007). These findings confirm known regions of CNAs in prostate cancer and localize additional regions and possible genes (e.g., BNIP3L, WWOX, and GATM) that may help to clarify the genetic basis of prostate cancer aggressiveness.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21965145      PMCID: PMC3209417          DOI: 10.1002/gcc.20932

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  20 in total

1.  A role for the WWOX gene in prostate cancer.

Authors:  Haiyan R Qin; Dimitrios Iliopoulos; Shuho Semba; Muller Fabbri; Teresa Druck; Stefano Volinia; Carlo M Croce; Carl D Morrison; Russell D Klein; Kay Huebner
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

2.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.

Authors:  R B Jenkins; J Qian; M M Lieber; D G Bostwick
Journal:  Cancer Res       Date:  1997-02-01       Impact factor: 12.701

3.  Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array.

Authors:  Wennuan Liu; Baoli Chang; Jurga Sauvageot; Latchezar Dimitrov; Marta Gielzak; Tao Li; Guifang Yan; Jishan Sun; Jielin Sun; Tamara S Adams; Aubrey R Turner; Jin Woo Kim; Deborah A Meyers; Siqun Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Genes Chromosomes Cancer       Date:  2006-11       Impact factor: 5.006

4.  Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP.

Authors:  B Z Yuan; M J Miller; C L Keck; D B Zimonjic; S S Thorgeirsson; N C Popescu
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

5.  Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism.

Authors:  Benjamin A Rybicki; Christine Neslund-Dudas; Nora L Nock; Lonni R Schultz; Ludmila Eklund; James Rosbolt; Cathryn H Bock; Kristin G Monaghan
Journal:  Cancer Detect Prev       Date:  2006-10-25

6.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

Authors:  Sven Perner; Francesca Demichelis; Rameen Beroukhim; Folke H Schmidt; Juan-Miguel Mosquera; Sunita Setlur; Joelle Tchinda; Scott A Tomlins; Matthias D Hofer; Kenneth G Pienta; Rainer Kuefer; Robert Vessella; Xiao-Wei Sun; Matthew Meyerson; Charles Lee; William R Sellers; Arul M Chinnaiyan; Mark A Rubin
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

7.  Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer.

Authors:  Xiaodong Sun; Henry F Frierson; Ceshi Chen; Changling Li; Qimei Ran; Kristen B Otto; Brandi L Cantarel; Brandi M Cantarel; Robert L Vessella; Allen C Gao; John Petros; Yutaka Miura; Jonathan W Simons; Jin-Tang Dong
Journal:  Nat Genet       Date:  2005-03-06       Impact factor: 38.330

8.  Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.

Authors:  Ming Guan; Xiaoling Zhou; Nikolaos Soulitzis; Demetrios A Spandidos; Nicholas C Popescu
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

9.  DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies.

Authors:  Jishan Sun; Wennuan Liu; Tamara S Adams; Jielin Sun; Xingnan Li; Aubrey R Turner; Baoli Chang; Jin Woo Kim; Siqun Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Prostate       Date:  2007-05-15       Impact factor: 4.104

10.  Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array.

Authors:  N Tørring; M Borre; K D Sørensen; C L Andersen; C Wiuf; T F Ørntoft
Journal:  Br J Cancer       Date:  2007-01-23       Impact factor: 7.640

View more
  17 in total

1.  Copy number alteration burden predicts prostate cancer relapse.

Authors:  Haley Hieronymus; Nikolaus Schultz; Anuradha Gopalan; Brett S Carver; Matthew T Chang; Yonghong Xiao; Adriana Heguy; Kety Huberman; Melanie Bernstein; Melissa Assel; Rajmohan Murali; Andrew Vickers; Peter T Scardino; Chris Sander; Victor Reuter; Barry S Taylor; Charles L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

2.  Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells.

Authors:  Xiaoling Zhou; Xu-Yu Yang; Nicholas C Popescu
Journal:  Biochem Biophys Res Commun       Date:  2012-03-07       Impact factor: 3.575

3.  Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations.

Authors:  Daniella Bianchi-Frias; Ryan Basom; Jeffrey J Delrow; Ilsa M Coleman; Olga Dakhova; Xiaoyu Qu; Min Fang; Omar E Franco; Nolan G Ericson; Jason H Bielas; Simon W Hayward; Lawrence True; Colm Morrissey; Lisha Brown; Neil A Bhowmick; David Rowley; Michael Ittmann; Peter S Nelson
Journal:  Mol Cancer Res       Date:  2016-01-11       Impact factor: 5.852

4.  DLC1 interaction with α-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activity.

Authors:  Veenu Tripathi; Nicholas C Popescu; Drazen B Zimonjic
Journal:  Mol Cell Biol       Date:  2012-04-02       Impact factor: 4.272

Review 5.  WWOX: a fragile tumor suppressor.

Authors:  Morgan S Schrock; Kay Huebner
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-22

6.  A Panel of Genes Identified as Targets for 8q24.13-24.3 Gain Contributing to Unfavorable Overall Survival in Patients with Hepatocellular Carcinoma.

Authors:  Kun Zhao; Yu Zhao; Jia-Yi Zhu; Hui Dong; Wen-Ming Cong; Yi Yu; Hui Wang; Zhong-Zheng Zhu; Qing Xu
Journal:  Curr Med Sci       Date:  2018-08-20

7.  Molecular and translational advances in meningiomas.

Authors:  Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

Review 8.  Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification.

Authors:  Jamie R Schoenborn; Pete Nelson; Min Fang
Journal:  Clin Cancer Res       Date:  2013-05-23       Impact factor: 12.531

9.  Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patients.

Authors:  Albert M Levin; Karla J Lindquist; Andrew Avila; John S Witte; Pamela L Paris; Benjamin A Rybicki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-02       Impact factor: 4.254

Review 10.  The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing.

Authors:  Alexander W Wyatt; Fan Mo; Yuzhuo Wang; Colin C Collins
Journal:  Asian J Androl       Date:  2013-03-18       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.